Every 10-Q that Tevogen Inc. Warrant (TVGNW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TVGNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVGNW filings page.
Tevogen Inc reported continuing losses as it advances its cell-therapy and AI-driven precision medicine programs. For the six months ended June 30, 2026, the company recorded a net loss of $11.2 million, improved from $15.9 million a year earlier, driven largely by a sharp reduction in general and administrative expenses to $4.6 million from $9.9 million. Research and development spending rose modestly to $6.4 million, reflecting ongoing work on lead candidate TVGN 489 and the broader pipeline.
Liquidity remains tight. Cash was $1.1 million at June 30, 2026, against $13.6 million in total liabilities and a stockholders’ deficit of $8.9 million. The company is relying on an unsecured related-party credit facility with a $6.4 million balance and $11.0 million still available, plus a remaining $7.0 million grant commitment from KRHP and an at-the-market equity program capped at $50 million. Management believes these sources will fund operations for at least 12 months but does not plan to initiate another clinical trial until it secures additional financing.
Tevogen executed a 1-for-50 reverse stock split in March 2026 and issued $3.0 million of pre-funded warrants and significant equity awards, resulting in substantial non-cash stock-based compensation of $6.1 million in the first half of 2026.
Tevogen Bio Holdings Inc. reported a Q1 2026 net loss of $5.4M, improved from $10.4M a year earlier, mainly due to sharply lower general and administrative stock-based compensation. Operating expenses fell to $5.4M from $10.4M, with research and development relatively stable around $3.1M.
The company had cash of $0.7M as of March 31, 2026 and used $2.7M in operating cash flow, funded by draws on a related-party loan facility and at-the-market stock sales. Management expects existing cash, a $14.0M undrawn loan capacity, a remaining $7.0M grant commitment, and $3.0M PIPE warrant proceeds in May 2026 to support operations for at least 12 months, but does not plan to start new clinical trials until further funding is raised.
The balance sheet shows a stockholders’ deficit of $9.8M and total liabilities of $14.8M, including $6.4M outstanding under the loan and $1.7M of notes payable that are in default but carry no additional default payments. During the quarter the company completed a 1-for-50 reverse stock split and ended with 4,168,705 common shares outstanding. Subsequent events include a private placement of prefunded warrants for 375,000 shares raising about $3.0M, and Nasdaq notices that its market value of listed and publicly held shares has fallen below continued listing thresholds, giving it until mid-October 2026 to regain compliance.
Tevogen Bio Holdings, Inc. reported interim financials showing limited operating cash and multiple financing arrangements supporting operations for the next 12 months. The company had $685,229 in cash at June 30, 2025 and raised $2,533,023 in net proceeds under an at‑the‑market Sales Agreement through August 13, 2025, plus a subsequent $1,000,000 capital contribution from KRHP. The Loan Agreement outstanding balance was $4,400,000 with $24,000,000 available for future draws; interest can be paid in stock and the Company issued 1,000,000 shares to the Patel Family as an inducement. Notes payable of $1,651,000 remain in default on technical repayment terms. The post‑merger capital structure includes preferred stock financings (Series A proceeds $2,000,000; Series C proceeds $6,000,000), large equity awards (Special RSU grant fair value $87,263,783), and 196,705,067 common shares reported outstanding. Management says it will not initiate clinical trials until additional funding is received.